UNSPSC 51182010: Nandrolone

This classification denotes a therapeutic androgen and anabolic steroid with the molecular formula C18H26O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6PG9VR430D, chemically known as estr-4-en-3-one, 17-hydroxy-, (17beta)- (9ci) but generally known as nandrolone, which bears US NIH Compound Identifier 9904. European Medicines Agency schedules Nandrolone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09148MIG.

UNSPSC 51182010 Nandrolone is a Commodity code encompassing anabolic steroid pharmaceuticals, though recent state and local procurement activity under this code focuses more broadly on generic multi-source pharmaceuticals and over-the-counter products supplied through established wholesale distribution networks. State and local governments procure nandrolone and related pharmaceutical products primarily through cooperative purchasing agreements that aggregate demand across multiple jurisdictions and healthcare facilities. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) administers the primary recent vehicle, managing contracts that serve participating state agencies, counties, cities, and local government healthcare operations. Vendors must meet rigorous compliance requirements including current Good Manufacturing Practices (cGMP) certification, Drug Supply Chain Security Act (DSCSA) compliance, FDA registration, and substantial insurance coverage ($5,000,000 commercial general liability, $2,000,000 network security and privacy liability, $2,000,000 professional liability). Products must be available through three authorized wholesalers—AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC—with chargeback systems and electronic data interchange (EDI) capability required.

The Minnesota Department of Administration's Office of State Procurement issued RFP S1070000015802 on January 20, 2026, with a response deadline of March 26, 2026, to establish multi-award contracts for generic pharmaceuticals and OTC products effective July 1, 2026. The RFP covers Minnesota and Oregon participating jurisdictions, with evaluation weighted 75 percent on price competitiveness, 10 percent on fixed pricing for the contract term, and 5 percent each on administrative compliance, EDI capability, and agreement to a 3 percent administrative fee. Vendors must submit detailed product information including National Drug Codes (NDC), SKUs, UPCs, strength, dosage form, packaging, and manufacturing location through the ePro procurement system, with pricing options including flat price, net price formats (NF30, NF60, NF90), or WAC-minus structures. The contract term is two years for new vendors with optional extensions, while incumbents' amendments extend through June 30, 2028. No specific set-aside designations were identified in the solicitation materials.